Antibodies News and Research

RSS

Natural SARS-CoV-2 infection induces more durable immunity than vaccination study suggests

Scientists from the USA have demonstrated that immunity induced by mRNA-based COVID-19 vaccines in previously SARS-CoV-2-infected people has the highest robustness and durability with cross-reactivity against different viral variants.

15 Sep 2021

Aptamers for Targeting SARS-CoV-2 Proteins

AMSBIO has further expanded its product range to help in the fight against COVID-19 with the introduction of a new range of aptamers targeting SARS-CoV-2 proteins to aid development of new kits and assays.

From AMS Biotechnology 15 Sep 2021

A sweet pill to swallow: oral nucleoside analog of Remdesivir improved SARS-CoV-2 pathogenesis in mice

A new study focused on in vitro antiviral activity in various cell models and in vivo therapeutic efficacy of oral GS-621763 in a mouse model of SARS-CoV-2 pathogenesis.

15 Sep 2021

Deep profiling of SARS-CoV-2 immune response amongst the mildly symptomatic

In a research paper recently uploaded to the medRxiv* preprint server by Capelle et al. (September 2nd, 2021), the immune response of mild and hospitalized COVID-19 patients is compared, finding that early T-cell response is a vital indicator of SARS-CoV-2 disease severity.

15 Sep 2021

Quantification of salivary IgG and IgA against SARS-CoV-2

Salivary antibody levels are many fold lower than found in blood serum, Immunoglobulin G (IgG) in the saliva is mainly sourced from leakage from the gingival surface and Immunoglobulin A (IgA) from mucosal membranes.

15 Sep 2021

Pregnancy complications with COVID-19

An important new article published in the Clinical Medicine Journal discusses pregnancy complicated with COVID-19.

14 Sep 2021

Prior symptomatic COVID-19 enhances mRNA vaccine response

A new paper describes the antibody responses in people who have already been infected with SARS-CoV-2 and are vaccinated as compared to the naïve.

14 Sep 2021

MS patients receiving aCD20 treatment mount robust T-cell responses to COVID-19 vaccines

New research shows that Multiple Sclerosis (MS) patients undergoing anti-CD20 (aCD20) treatment – which depletes the B cells that contribute to the MS attacks – are able to mount robust T-cell responses to the mRNA COVID-19 vaccines, despite having a muted antibody response to the vaccines.

14 Sep 2021

Low dose of Moderna COVID-19 vaccine generates durable immune response

A new study from La Jolla Institute for Immunology (LJI) scientists helps answer the question: how long does immunity against COVID-19 last in vaccinated people?

14 Sep 2021

Study explains confounding effects of different dosages and dosing protocols on COVID-19 vaccine efficacies

A recent study investigates the paradoxical effects of dosage and dosing interval on COVID-19 vaccine efficacy.

14 Sep 2021

Severe COVID-19 linked to increase in autoantibodies

Hospitalized COVID-19 patients are substantially more likely to harbor autoantibodies -;antibodies directed at their own tissues or at substances their immune cells secrete into the blood -; than people without COVID-19, according to a new study.

14 Sep 2021

mRNA BNT162b2 vaccine safe in immunocompromised patients

The clinical trial showed that about 72.2% of immunocompromised patients had detectable antibodies against SARS-CoV-2.

14 Sep 2021

Convalescent plasma shows no benefit in hospitalized COVID-19 patients

A new paper describes the results of a randomized controlled trial of CP in adult COVID-19 patients on oxygen when used within 12 days of the onset of respiratory symptoms.

14 Sep 2021

Impact of prior SARS-CoV-2 infection and vaccine on antibody levels: Texas survey

A collaborative team, led by principal investigator Dr. Eric Boerwinkle, at The University of Texas Health Science Center at Houston, School of Public Health is conducting a survey designed to assess the frequency of antibody-positive individuals across Texas. The TEXAS Coronavirus Antibody REsponse Survey (CARES) aims to look for antibodies in the blood made in response to natural SARS-CoV-2 infection or vaccination.

14 Sep 2021